Back to News & Events

Health Security Innovation Showcase – 10/18

The first virtual Health Security Innovation Showcase is being held on October 18 from 12 pm – 5 pm EDT to learn about high impact life science startups being supported by BARDA partners, including, CARB-X, the BARDA Accelerator Network, and the BARDA-J&J Blue Knight program. These companies are developing platform technologies in a variety of technology areas, including diagnostic tools, therapeutics/vaccines, advanced manufacturing, and clinical trial support.

Highlights of the event:

– A Keynote address by Dr. Gary Disbrow, Director of BARDA
– 5-minute pitches by each company, followed by 3 minutes of Q&A
– Overviews of BARDA programs supporting innovation in the health security space
– Opportunities for you to set up one-on-one partnering meetings with the presenting companies

The event platform will contain company profiles, pitch decks and live calendars to be used to facilitate and set up meetings. Once registered, additional details will be provided on how to access and view the details of the participating companies.

Click here to register*

*When your registration request is approved, you will receive an email from the event system asking you to log in and fill out your profile.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 1391 [post_author] => 3 [post_date] => 2015-02-05 13:34:47 [post_date_gmt] => 2015-02-05 13:34:47 [post_content] => The Center for Biotechnology at Stony Brook University has announced the appointment of Mohan Chellani, PhD, and Michael Bielski, MS, JD to the position of BioEntrepreneurs-In-Residence (B-EIR). Both Dr. Chellani and Mr. Bielski have extensive bioscience industry experience at the senior management level, and have successfully commercialized multiple academic innovations. Their roles as BEIRs is to identify technologies that have the potential to support company formation in the region. Each brings unique skills and perspectives to technology assessment and bioscience-startups. Dr. Chellani has over twenty years of experience in the diagnostics industry prior to his appointment as B-EIR, having served as VP, Scientific Affairs at Enzo Biochem, and as a Director and Advisor to Quest Diagnostics. He has also served as founder and CEO of two startup companies, Progen Life Sciences and Discitis Diagnostics. Dr. Chellani holds a PhD in Biochemistry and Molecular Biology from UMD-New Jersey and an MBA from Fordham University. Mr. Bielski has founded multiple technology companies, including co-founding NewLeaf Symbiotics, Inc., an agricultural biotechnology company that has raised over $25M in venture capital. He also served as the Assistant Director for Science and Technology Commercialization at the Center for Biotechnology for six years prior to pursuing his entrepreneurial ventures. Mr. Bielski holds a JD and an MS in Neuroscience from Syracuse University. Both Dr. Chellani and Mr. Bielski will conduct due diligence to identify a technology or technologies around which they may build a company. If successful, they will also be provided with access to a technology development budget that will help them position the technology for commercialization. B-EIRs also have access to the Center's business and technology development support staff to help develop appropriate business strategies. Ultimately, the goal is to help the company prepare for SBIR/STTR grant opportunities, and Angel and VC investment. Read the full press release. [post_title] => Center for Biotechnology Continues to Expand B-EIR Program [post_excerpt] => Diagnostics Executive Mohan Chellani and Entrepreneur Michael Bielski selected to evaluate emerging SBU technologies [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => center-for-biotech-continues-to-expand-b-eir-program [to_ping] => [pinged] => [post_modified] => 2023-05-13 16:06:55 [post_modified_gmt] => 2023-05-13 16:06:55 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1391 [menu_order] => 215 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2045 [post_author] => 3 [post_date] => 2016-02-10 19:43:41 [post_date_gmt] => 2016-02-10 19:43:41 [post_content] => Celmatix has announced a collaboration with 23andMe, the leading personal genetics company, with the goal of improving infertility outcomes. This collaboration will accelerate the launch of Celmatix’s tests, which will aim to provide physicians with a comprehensive genetic lens on infertility. This will also enable the development of early screening tests which will help OBGYNs identify women who are at risk for premature decline of their ovarian function, which has both infertility and broader health implications. Read the announcement here. [post_title] => Celmatix to Partner with 23andMe [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => 2045-2 [to_ping] => [pinged] => [post_modified] => 2016-03-29 19:45:50 [post_modified_gmt] => 2016-03-29 19:45:50 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2045 [menu_order] => 191 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3469 [post_author] => 3 [post_date] => 2020-05-05 08:25:54 [post_date_gmt] => 2020-05-05 08:25:54 [post_content] => *This list will be updated as opportunities arise. (Updated 7.21.20)

NIH & NIAD Limited Competition Emergency Awards: Shared PPPE Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies

The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”. Rolling deadline - details here: https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html#_Section_I._Funding

NIH & NIBIB Rapid Acceleration of Diagnostics (RADx) 

Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Learn more: https://www.poctrn.org/radx

Pfizer COVID-19 Competitive Grant Program 

Pfizer has released a Request for Proposals (RFP) to provide financial support for organizations producing independent educational programs and quality improvement initiatives designed to combat this evolving crisis. This competitive grant program from Pfizer Global Medical Grants (GMG) involves a publicly posted RFP that provides details regarding a specific area of interest, sets timelines for review and approval, and uses an internal review process to make final grant decisions. For this RFP, organizations are invited to submit an application addressing the gaps in knowledge and practice of COVID-19 management as outlined here.

Mozilla launches COVID-19 Solutions Fund

Mozilla has created a COVID-19 Solutions Fund as part of the Mozilla Open Source Support Program (MOSS). Through this fund, awards of up to $50,000 each will be provided to open source technology projects which are responding to the COVID-19 pandemic in some way. As part of the COVID-19 Solutions Fund, applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation)will be accepted. More details here. Application here.

NYS COVID-19 Manufacturing Grants for Masks, Ventilators

The COVID-19 Manufacturing Grants, part of the Jeff Lawrence Innovation Fund, are designed to aid existing New York State small to medium-sized manufacturing companies that can meet prevailing FDA requirements and can quickly accelerate production of personal protective equipment and respiratory care equipment that has been depleted due to the COVID-19 outbreak. Full details here. (Deadline April 17, 2020)

NIBIB announces three COVID-19 Notices of Special Interest

Multiple Notices of Special Interest include administrative supplements and emergency competitive revisions funding for current grantees; SBIR/STTR opportunities; and investigator-initiated research opportunities. Current grantees and new applicants are encouraged to apply immediately. More here.

Fast Grants 

Fast Funding for COVID-19 Science. Scientist at academic institutions currently working on a COVID-19 related project and in need of funding are invited to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. More: fastgrants.org

NIH COVID-Specific Funding Opportunities (Update) 

Multiple Agency NOSI listed here. National Institute of Allergy and Infectious Diseases: Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) RFA-AI-20-028 Administrative Supplements to Existing NIH Grants and Cooperative Agreements: Funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award. More. Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements: Funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner. More.

NSF Request for SBIR/STTR Phase I Proposals Addressing COVID-19

Phase I proposals should focus on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis. Areas of research include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. To apply, you must first develop and submit a Project Pitch at https://seedfund.nsf.gov/apply/. Assuming your pitch is approved, you will be invited by NSF to submit a grant application. More information here.

Department of Defense - Newton Award for Transformative Ideas during the COVID-19 Pandemic

This award will be presented to a single investigator or team of up to two investigators that develops a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. BRO-20-NEWTON (5/5/20 deadline)

COVID-19 Therapeutics Accelerator

Established by The Gates Foundation and Wellcome, this initiative aims to accelerate and evaluate new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The COVID-19 Therapeutics Accelerator will not be conducting a traditional funding call. To learn more about the funding process, or how to invest in the accelerator, contact epidemics@wellcome.ac.uk 

Small Business Assistance Programs

Stony Brook University Small Business Development Center is available to assist business owners trough the abundance of resources available for your particular business/industry and to avoid the most common mistake of incomplete or inaccurate Economic Injury Disaster Assistance Loan applications. Visit their website for more information.

Stony Brook University CEAS Student Opportunity: COVID-19 Innovation Teams

Stony Brook University's College of Engineering and Applied Sciences' Vertically Integrated Project Program is focusing special attention on the urgent needs of the COVID-19 pandemic. Learn more.

Innovate2Ventilate: The CoVent-19 Challenge

The CoVent-19 Challenge invites engineers, innovators, designers, and makers to produce rapidly deployable designs for mechanical ventilators. Launching on April 1, 2020, the deadline for the open-entry round of competition is May 1, 2020. Round 2 of the challenge is an invitation-only competition with a deadline of June 1, 2020. More: coventchallenge.com

COVID-19 Funding Opportunities - Summary via Stony Brook University Research 

The funding opportunities listed here are posted on the Pivot databasegrants.govNIH Guide for Grants and Contracts, and nsf.gov. Detailed information on NIH funding opportunities and other guidance related to COVID-19 can be found here. Investigators should check eligibility and obtain any necessary approvals before applying.

Stony Brook University Faculty Funding Opportunity 

Stony Brook University Office of the Vice President for Research, together with the Institute for Engineering-Driven Medicine, announce this special initiative COVID-19 seed funding opportunity. The purpose of this program is to seed research that has a direct connection to the current COVID-19 pandemic.Applications are due April 10. Details about eligibility, award amounts and application process can be found here.

Contacting New York State to offer your COVID-19 Resource: 

Businesses with capabilities relevant to needed medical equipment and supplies email to COVID19supplies@esd.ny.gov. Businesses interested in selling products to the state should contact Simonida Subotic at 646-522-8477 or covid19supplies@exec.ny.gov. Businesses interested in receiving state funding to manufacture PPE products should contact Eric Gertler at 212-803-3100 or COVID19supplies@esd.ny.gov.

Indie Bio Coronavirus Initiative 

Indie Bio is seeking up to 8 startups to receive a minimum of $250,000 each to pursue the development of diagnostics, therapeutics, vaccines, disinfection, and other solutions addressing the worldwide problem of emerging infectious diseases. More.

BARDA COVID-19 Funding Opportunities

BARDA BAA (no funding limit)  Novel Coronavirus EZ-BAA (solicitations for funding up to $750K)

Research Foundation of SUNY COVID-19 Funding Opportunities 

**NEW**  SUNY Research Seed Grant Program RFP #20-03-COVID & Submission form. Aggregate list of opportunities: https://www.rfsuny.org/about-us/covid-19/covid-19-funding/

Biotechnology Innovation Organization (BIO) Coronavirus Resources

Resource page includes Business Resource Center, Service Provider Directory and Coronoavirus Hub where companies can share what they need and how they can help.

CAD $200K ventilator design challenge for COVID-19 patients

the Challenge is lead by Code Life.ca and the Montreal General Hospital foundations. The designs are due end of March 2020. The details and rules are posted there, and participants can sign up to begin: https://www.agorize.com/en/challenges/code-life-challenge/ OTHER CHALLENGES Business Incubator Association of New York State - Innovate to Ventilate  Hauppauge Industrial Association of Long Island (HIA-LI) Pivot to PPE RESOURCES COVID-19 Open Research Dataset (CORD-19) Ginkgo commits $25M of free access to platform for partner COVID-19 projects   [post_title] => COVID-19 Funding and Resource Opportunities [post_excerpt] => An aggregate list of COVID-19 related funding opportunities and technology and business related resources. This list will be updated as opportunities arise. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => covid-19-resources [to_ping] => [pinged] => https://indiebio.co/indiebio-covid-response/ [post_modified] => 2020-07-21 13:20:53 [post_modified_gmt] => 2020-07-21 13:20:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3469 [menu_order] => 71 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Center for Biotechnology Continues to Expand B-EIR Program

More Information

Celmatix to Partner with 23andMe

More Information

COVID-19 Funding and Resource Opportunities

More Information